Readystate Asset Management LP Takes Position in Vera Therapeutics, Inc. $VERA

Readystate Asset Management LP purchased a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 295,114 shares of the company’s stock, valued at approximately $12,663,000. Readystate Asset Management LP owned 0.41% of Vera Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in VERA. Los Angeles Capital Management LLC purchased a new stake in Vera Therapeutics in the fourth quarter worth approximately $46,000. Aster Capital Management DIFC Ltd purchased a new stake in Vera Therapeutics during the 4th quarter valued at $71,000. Quantbot Technologies LP purchased a new stake in Vera Therapeutics during the 2nd quarter valued at $51,000. Nykredit A S bought a new position in shares of Vera Therapeutics during the 2nd quarter valued at $97,000. Finally, Sandia Investment Management LP bought a new position in shares of Vera Therapeutics during the 4th quarter valued at $127,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $35.89 on Monday. Vera Therapeutics, Inc. has a one year low of $21.96 and a one year high of $56.05. The stock’s fifty day moving average is $35.86 and its 200 day moving average is $37.42. The stock has a market cap of $2.59 billion, a P/E ratio of -6.12 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same period in the previous year, the company earned ($1.20) EPS. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -6.45 earnings per share for the current year.

Insider Activity

In related news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 83,250 shares of company stock worth $3,307,800. Insiders own 15.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group restated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Needham & Company LLC set a $125.00 target price on Vera Therapeutics in a report on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Raymond James Financial reissued a “strong-buy” rating and issued a $84.00 target price on shares of Vera Therapeutics in a research report on Tuesday, August 11th. Finally, Bank of America upped their price target on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.15.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.